Xylyx Bio, Inc.
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Respiratory
Xylyx Bio is developing first-in-class human lung grafts to significantly increase the number of lungs available for life-saving transplantation, increase hospital transplant volume and revenue, and reduce payor costs associated with end-stage disease. The company’s lead program (Inspirex Lung) completed IND-enabling studies, has been granted FDA orphan designation, and is poised for historic first-in-human transplants, with parallel pipeline development in liver, kidney, and heart. Next steps include IND submission and first-in-patient transplants – major value-adding milestones on the path to regulatory approval in the $15B U.S. near-term obtainable market. The company is targeting an exit within 3-5 years with a 10x revenue return.
Company HQ City:
Brooklyn
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
Our lead product, Inspirex Lung, is a fully functional, anatomically compatible whole lung graft for life-saving clinical lung transplantation.
CEO
Andrea Nye MPH MBA
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
0
When you expect your next catalyst update?
October 2026
What is your next catalyst (value inflection) update?
IND clearance and first-in-human transplants
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}